DC-ATL, Good one! From casual reading, Mesoblast seems to be in a tough spot. After they showed some good data in treatment of peds GvHD, FDA asked for a larger trial and, oh, by the way, tell us how it works. The latter issue may take a while to sort out.
So we get Dr. Rahman, and we have tons of Mechanism of Action info. My head spins at the thought of LL taking care of the auto-immune part of Ohm20's disease pile. Black-Ops sized numbers would quickly appear on the near horizon. Best.
News 
Market Data 
Discover 
